Iktos, Teijin Pharma to co-develop new technology for small molecule drug discovery

French agency Iktos, an organization specialised in Synthetic Intelligence (AI) for brand spanking new drug design, and Japan’s Teijin Pharma Restricted, the core firm of the Teijin Group’s healthcare enterprise that gives complete healthcare providers to enhance the standard of life, have introduced a strategic collaboration settlement in Synthetic Intelligence for brand spanking new drug design.

Beneath the settlement, Iktos generative modelling expertise can be applied and utilized to a number of Teijin Pharma’s small molecule drug discovery tasks to expedite the identification of potential pre-clinical candidates. Iktos and Teijin Pharma will collaborate in creating new AI expertise aiming to convey additional enchancment and pace to the drug design course of, leveraging Iktos’ proprietary know-how in AI for Pc Aided Drug Design (CADD) and complementing Teijin’s analysis and improvement capabilities.

Primarily based on the current drastic demographic change and elevated well being consciousness, Teijin Pharma is dedicated to offering healthcare options within the precedence fields of bone, joint, rehabilitation, neurology, respiratory, cardiovascular and metabolic ailments. Creating modern medication is likely one of the firm’s core enterprise methods and Teijin Pharma is now specializing in strengthening technological basis for small molecule medication that play main roles among the many drug modalities for modern drug discovery.

Leave a Comment